GleamWall
中文EN

EMED Electromedical Technologies, Inc

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1715819 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-35.1%
TTM net income YoY46.3%
TTM EPS YoY—
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—

Margins

Gross margin75.1%
Operating margin-109.6%
Net margin-182.0%
FCF margin—
EBITDA margin-109.6%

Returns

ROE—
ROA-236.0%
ROIC (approx.)—
Asset turnover1.30x

Leverage & solvency

Liabilities / assets804.1%
Debt / equity—
Current ratio0.07x
Interest coverage-4.38x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-217.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-302023Q12023-03-312022Q4*2022-12-31
Income statement
Revenue$42,526$237,645$290,244$351,595$323,613$294,954$378,646$423,148
Cost of revenue$11,881$64,390$72,857$80,651$72,437$62,519$87,696$90,219
Gross profit$30,645$173,255$217,387$270,944$251,176$232,435$290,950$332,929
SG&A expense$411,683$425,100$372,263$493,915$490,205$573,838$1.55M$590,261
Operating income-$381,038-$251,845-$154,876-$222,971-$239,029-$341,403-$1.26M-$257,332
Interest expense$54,914$58,301$59,320$58,346$162,121$284,487$388,201$280,655
Net income-$724,643$231,236-$836,274-$348,657-$376,720-$1.46M-$456,063-$830,087
EBITDA-$381,038-$251,845-$154,876-$222,971-$239,029-$341,403-$1.26M-$251,863
EPS (basic)0.000.00-0.00—0.000.00-0.00—
EPS (diluted)—0.00-0.00—0.000.00-0.00—
Weighted avg. shares (diluted)—1.94B464.82M—466.22M335.50M240.57M—
Balance sheet
Cash & equivalents$34,809$116,931$78,843$87,704$138,477$416,256$1.24M$368,425
Receivables$7,251$4,338$3,501$4,399$9,200$25,788$5,826$9,444
Inventory$24,256$31,681$46,561$68,517$131,310$113,151$159,704$62,061
Current assets$305,361$389,224$419,375$449,185$543,004$881,996$1.57M$647,802
PP&E, net$149,705$149,705$149,705$149,705$149,705$149,705—$705,469
Total assets$568,813$664,959$707,022$748,383$853,403$1.03M$1.57M$1.35M
Current liabilities$4.36M$3.83M$4.15M$3.36M$3.09M$3.15M$2.44M$2.92M
Long-term debt———$150,000———$671,525
Total debt———$150,000———$671,525
Total liabilities$4.57M$4.06M$4.40M$3.62M$3.37M$3.31M$2.60M$3.57M
Shareholders' equity-$4.00M-$3.40M-$3.69M-$2.87M-$2.52M-$2.28M-$1.03M-$2.22M
Net debt———$62,296———$303,100
Shares outstanding725.35M566.11M486.48M463.29M471.50M432.49M296.89M189.78M
Cash flow statement
Operating cash flow-$30,829$108,927-$158,361-$50,948-$277,779-$635,930-$452,736-$33,099
Capital expenditure———$0$0———
Free cash flow———-$50,948-$277,779———
Investing cash flow———$0$0-$149,705$1.89M—
Financing cash flow-$51,293-$70,839$149,500$175$0-$33,136-$575,250-$57,391
Depreciation & amortization$0$0$0$0$0$0$4,557$5,469
Stock-based compensation———$0$0$0$715,000$25,000

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.